Chronic activation of B-cell receptor (BCR) signaling via Bruton tyrosine kinase (BTK) is largely considered to be one of the primary mechanisms driving disease progression in B–Cell lymphomas. This evidence concerns the gene BCR and B-cell non-Hodgkin lymphoma.